Skip to main content

Advertisement

Figure 2 | Breast Cancer Research

Figure 2

From: Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF

Figure 2

Tissue factor pathway inhibitor (TFPI) and tissue factor (TF) plasma levels across molecular breast cancer subtypes. Box and whisker plot showing the distribution of plasma levels of total TFPI and free TFPI (A) and TF (B) across the following intrinsic molecular subtypes of 148 of the 152 breast cancer patients; basal (n = 24), human epidermal growth factor 2 (HER2) HER2-enriched (n = 15), luminal A (n = 62), luminal B (n = 39) and normal-like (n = 8). P-values for multi-group comparison are indicated.

Back to article page